Yili launches Pro-Kido infant formula expanding its footprint into China

CHINA – Hohhot-based dairy company Yili has launched Pro-Kido Aronurish Infant Formula, marking its first entry into the local market. 

The new product launch was accompanied by a strategic partnership between Yili and Mannings, Hong Kong’s largest health and beauty retailer, to strengthen its presence and outreach in the local market.

Zhang Yipeng, Vice President of Yili Group, said, “Yili sees Hong Kong as an international gateway and looks forward to working with global partners to seize emerging opportunities and deliver high-quality, nutritious, and delicious products to consumers worldwide.”

Pro-Kido Infant Formula is a premium formula developed by Yili Group, designed to provide comprehensive nutrition for infants.

It has Human Milk Oligosaccharides (HMO) + innovation ecosystem, supporting infant gut health and immunity, contains α-lactalbumin and β-casein, along with multiple nucleotide patents. Additionally, it supports immune health, brain development, and digestion through advanced breast milk research.

The product is manufactured at Yili’s Modern Intelligence Health Valley facility. The facility integrates equipment and technologies from over ten countries, leading the industry in scale, innovation and digital intelligence.

Wu Zhijun, President of Eurofins Scientific Group (China), stated that Aronurish Infant Formula has undergone over 300 quality and safety tests, with all results meeting international standards.

Research and development

As part of the company’s ongoing breast milk research, Dr. Ignatius Szeto, Assistant President of Yili Group and Head of Yili Global Maternal and Infant Nutrition Research Centre, presented the company’s Four-in-One comprehensive nutrition strategy and latest findings from its HMOs+ innovation ecosystem.

A white paper titled Key Achievements in Breast Milk Research, co-developed with academic experts, was also released. It outlines 13 notable findings, including the first accurate profiling of the amino acid composition of Chinese breast milk and the discovery of the link between HMOs and infant gut microbiota.

FY2024

Recently, the group reported a total revenue of 115.78 billion yuan (US$15.98 billion) in FY2024, further solidifying its position as Asia’s top dairy producer.

Its liquid milk business generated a revenue of 75.003 billion yuan (US$10.35 billion), consolidating its leading position and expanding its scale advantages.

The ice cream segment reported a revenue of 8.721 billion yuan (US$1.20 billion), securing the top spot in both revenue and market share for the 30th consecutive year.

The milk powder and related businesses achieved a record-high revenue of 29.675 billion yuan (US$4.10 billion), with milk powder sales maintaining the leading position in China, and goat milk formula ranking first globally in both sales volume and revenue.

Subscribe to receive our email newsletters with the latest news and insights from Africa, Middle East and around the world. SUBSCRIBE HERE